Drugs and Devices

FDA approves new indication for imaging agent

On June 13, the U.S. Food and Drug Administration (FDA) a new use for Lymphoseek (technetium 99m tilmanocept) Injection, a radioactive diagnostic imaging agent used to help determine the extent that squamous cell carcinoma has spread in the body’s head and neck region. Lymphoseek can now be used to guide “sentinel” lymph node biopsy in patients with cancer of the head and neck. This new indication will allow for the option of more limited lymph node surgery in patients with sentinel nodes negative for cancer. Read more.


Related Articles:

Leave a Reply

You have to agree to the comment policy.

 

Shares